MGMT and glioma: Considering that reduced expression or silencing of MGMT gene due to promoter methylation in glioma specimens increased median overall survival after temozolomide of 6.4 months (34) and of 15.1 months comparing the group of non-methylated versus that of highly methylated tumor samples (50), reduction of MGMT expression in patients presenting non-methylated MGMT promoter could be of relevant benefit in relation to the pace of the advancements in the therapy of this specific malignant tumor.